|
1) 日本高血圧学会高血圧治療ガイドライン作成委員会, 編. 高血圧治療ガイドライン2009
|
|
|
|
|
2) Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Inter-vention For Endpoint reduction in hypertension study. J Hypertens. 2002; 20: 1879-86
|
|
|
|
|
3) Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363: 2022-31
|
|
|
|
|
|
4) Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension. 2008; 51: 393-8
|
|
|
|
|
|
5) Folli F, Kahn CR, Hansen H, et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II cross-talk. J Clin Invest. 1997; 100: 2158-69
|
|
|
|
|
|
6) Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insu-lin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004; 43: 1003-10
|
|
|
|
|
|
7) Nickenig G, Röling J, Strehlow K, et al. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mecha-nisms. Circulation. 1998; 98: 2453-60
|
|
|
|
|
|
8) Iwai M, Tomono Y, Inaba S, et al. AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atheroscle-rotic mice. Am J Hypertens. 2009: 22: 784-91
|
|
|
|
|
|
9) Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gam-ma agonists. J Clin Invest. 2000; 106: 467-72
|
|
|
|
|
|
10) Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angio-tensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004; 43: 993-1002
|
|
|
|
|
|
11) Fujimoto M, Masuzaki H, Tanaka T, et al. An angiotensin II AT1 receptor antagonist, telmisar-tan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004; 576: 492-7
|
|
|
|
|
|
12) Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system in-creases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003; 42: 76-81
|
|
|
|
|
|
13) Tikellis C, Wookey PJ, Candido R, et al. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes. 2004; 53: 989-97
|
|
|
|
|
|
14) Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle" region for nonproteolytic activation of prorenin. J Clin Invest. 2004; 114: 1128-35
|
|
|
|
|
|
15) Lastra G, Habibi J, Whaley-Connell AT, et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin over-expression. Endocrinology. 2009; 150: 2561-8
|
|
|
|
|
|
16) Nagai Y, Ichihara A, Nakano D, et al. Possible contribution of the non-proteolytic activation of prorenin to the development of insulin resistance in fructose-fed rats. Exp Physiol. 2009; 94: 1016-23
|
|
|
|
|
|
17) Kouyama R, Suganami T, Nishida J, et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology. 2005; 146: 3481-9
|
|
|
|
|
|
18) Giani JF, Mayer MA, Muñoz MC, et al. Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am J Physiol Endocrinol Metab. 2009; 296: E262-71
|
|
|
|
|
|
19) Santos SH, Fernandes LR, Mario EG, et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes. 2008; 57: 340-7
|
|
|
|
|
|
20) Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009; 325: 612-6
|
|
|
|
|
|
21) AbdAlla S, Lother H, Langer A, et al. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of athero-sclerosis. Cell. 2004; 119: 343-54
|
|
|
|
|